Available for your adult patients with severe active anca-associated vasculitis (GPA/MPA)
Turn to PrTAVNEOS®
PrTAVNEOS® (avacopan capsules) is indicated for the adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard background therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.1
A treatment option in AAV (GPA/MPA)
Click here for additional information and a link to the Product Monograph discussing:
- Relevant warnings and precautions regarding increased risk for cardiac disorders with certain treatment regimens; gastrointestinal symptoms; risk of hepatic injury; not recommended for patients with activated, untreated, and/or uncontrolled chronic liver disease; angioedema; immunization with live vaccines; avoid use in patients with active serious infection, including localized infections; obtain live function tests and Hepatitis B virus serology before initiating treatment; pregnancy; women of childbearing potential not using contraception; and breast-feeding.
- Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.
AAV = anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
Reference:
1. TAVNEOS Product Monograph. Otsuka Canada Pharmaceutical Inc.